Recent publications on Residual Risk

In the Dyslipidemia International Survey-China survey, over 50% of patients had persistent atherogenic dyslipidaemia despite attainment of low-density lipoprotein cholesterol (LDL-C) goal on statin therapy. This report analysed data from 22,039 patients receiving statin monotherapy, enrolled at 122 hospitals in China. Atherogenic dyslipidaemia was defined as triglyceride levels ?1.7mmol/L and/or low levels of high-density lipoprotein cholesterol (men: <1.0mmol/L; women: <1.3mmol/L). Based on the US National Cholesterol Education Program Adult Treatment Panel III criteria, of 13,088 patients who attained LDL-C goals, 7,134 patients (55%) had residual atherogenic dyslipidaemia. Results were similar using the Chinese guideline for the management of dyslipidemia: 13,551 patients reached LDL-C goal, of whom 7,719 (57%) patients had atherogenic dyslipidaemia. The intensity of statin therapy did not affect the prevalence of atherogenic dyslipidaemia. These findings highlight the need for renewed awareness of atherogenic dyslipidaemia in this region.